R.PR
REGISTERED-PRINCIPAL REGISTER
01/18/2022
Back to search
Official data from USPTO
LYVEAH
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
20
Latest update
01/18/2022
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
12/21/2020
Registration date
01/18/2022
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/18/2022
Last transaction
01/18/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
16
Owner location
Marburg, DE
Examiner
SNAPP, TINA LOUISE
Law office
M70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
CSL Behring GmbH
Representatives
Scott D. Woldow SMITH, GAMBRELL & RUSSELL, LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for treating von Willebrand diseasehemophiliaprimary immunodeficiencyhereditary angioedemafibrinogen deficiencyAlpha 1 antitrypsin deficiencyinflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophiliapharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophiliapharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophiliaa blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodiesdiagnostic kits consisting primarily of monoclonal antibodiesbuffersreagents for use in disease testing; blood for medical purposes; cell cultures for medical purposescells for medical or clinical use; cell cultures for medical purposesliving cells for medical use; cell cultures for medical purposesstem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditionsrespiratory conditionspneumoniacovid-19influenza; Pharmaceutical preparationsantibody for the treatment of acute respiratory distress syndromeARDS; pharmaceutical preparationsantibody for the treatment of Idiopathic Pulmonary FibrosisIPF and Interstitial Lung DiseasesILD; Pharmaceutical preparationsantibody for the treatment of Hereditary AngioedemaHAE
Publications
History of USPTO decisions and trademark events.
20 publications found
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/02/2021
PUBO
PUBLISHED FOR OPPOSITION
11/02/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/13/2021
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
09/29/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/29/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
09/29/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/29/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
09/29/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/29/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/29/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/29/2021
ALIE
ASSIGNED TO LIE
09/28/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/22/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/23/2021
GNRT
NON-FINAL ACTION E-MAILED
06/23/2021
CNRT
NON-FINAL ACTION WRITTEN
06/23/2021
DOCK
ASSIGNED TO EXAMINER
06/16/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/05/2021
NWAP
NEW APPLICATION ENTERED
12/24/2020
Continuous trademark protection
Get notified about every new filing that threatens LYVEAH or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.